Have a personal or library account? Click to login
Hypertensive Crisis in Patients with Acute Intermittent Porphyria Cover

Hypertensive Crisis in Patients with Acute Intermittent Porphyria

Open Access
|Feb 2020

References

  1. Sassa S. Modern diagnosis and management of the porphyrias. British Journal of Haematology, 2006; 135: 281–292
  2. Mehta M., Rath G.P., Padhy U.P., Marda M., Mahajan C. and Dash H.D. Intensive care management of patients with acute intermittent porphyria: clinical report of four cases and review of literature. Indian J Crit Care Med. 2010; 14(2): 88–91.
  3. Handschin, C., Lin, J., Rhee, J., et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell, 2005;122: 505–515.
  4. Innala E., Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. Journal of Internal Medicine. 2011; 269(5):538–545
  5. Stölzel U., Stauch T., Doss M.O. Porphyrias. Internist (Berl). 2010; 51(12): 1525–33
  6. Kovačević Z., Janićijević Petrovic M., Šarenac T., Mladenović V., Stojilković T. Acute intermittent Porphyria. PONS Med J. 2012; 9 (3):110–113.
  7. Balwani M., Desnick R.J. The porphyrias: advances in diagnosis and treatment. Hematology 2012;120: 19–27
  8. Anderson K.E., Bloomer J.R., Bonkovsky H.L., et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005 Mar 15;142(6):439–50.
  9. Sardh E., Harper P., Andersson D.E., Floderus Y. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med. 2009 Mar;20(2):201–7.
  10. Harper P., Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol. 2007 Dec;10(6):444–55.
  11. González-Arriaza H.L., Bostwick J.M. Acute Porphyrias: A Case Report and Review. Am J Psychiatry 2003; 160 (3):450–8.
  12. Puy H., Gouya L., Deybach J.C. Porphyrias. Lancet. 2010 Mar.13;375(9718): 924–37.
  13. Jose J, Saravu K, Shastry B A, Jimmy B. Drug use in porphyria: a therapeutic dilemma. Singapore Med J 2008; 49(10): e272–e275
  14. Andersson C., Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. Journal of Internal Medicine. 1994; 236(2):169–175
  15. Singh V., Sud K., Kohli H.S., Gupta K.L., Sakhuja V. Acute Intermittent Porphyria : An Unusual Cause of Malignant Hypertension. JAPI. 2003; (51): 225–226.
  16. Cinemre H, Korkmaz U, Alcelik A, Onder E, Gungor A. Safety of amlodipine use in patients with acute intermittent porphyria. Br J Clin Pharmacol 2007;64(2): 246–247
  17. Lambrecht R.W., Gildemeister O.S., Williams A., Pepe J.A., Tortorelli K.D., Bonkovsky H.L. Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation: implications for clinical porphyria. Biochem Pharmacol. 1999 Sep 1;58(5):887–96
DOI: https://doi.org/10.1515/sjecr-2017-0039 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Language: English
Submitted on: Nov 25, 2014
|
Accepted on: Jul 17, 2017
|
Published on: Feb 22, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Olivera Andrejic, Rada Vucic, Violeta Iric Cupic, Goran Davidovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

AHEAD OF PRINT